Third Rock Ventures III, L.P. 3
3 · Nurix Therapeutics, Inc. · Filed Jul 23, 2020
Insider Transaction Report
Form 3
Third Rock Ventures III, L.P.
10% Owner
Holdings
Series B Preferred Stock
Exercise: $0.00→ Common Stock (4,508,333 underlying)Series D Preferred Stock
Exercise: $0.00→ Common Stock (39,216 underlying)Serries A-2 Preferred Stock
Exercise: $0.00→ Common Stock (875,000 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
- [F2]The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.